Skip to main content
Clinical Trials/JPRN-jRCT1080221967
JPRN-jRCT1080221967
Completed
Phase 4

The post-marketing clinical randomized study of eldecalcitol on fall-related physical performance in Japanese osteoporotic patients with frailty

Chugai Pharmaceutical Co., Ltd.0 sites124 target enrollmentNovember 19, 2012

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Chugai Pharmaceutical Co., Ltd.
Enrollment
124
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

A randomized, open-label, controlled clinical trial has been conducted with 124 female patients aged 65 or over with osteoporosis. Patients were randomly assigned to receive either 0.75 mcg of ELD once-a-day or 35 mg of ALN once-a-week for 24 weeks. The primary endpoint was the change in a postural balance index, adjusted composite equilibrium score (CES) of sensory organization test (SOT). There was no statistically significant difference between the two groups.

Registry
who.int
Start Date
November 19, 2012
End Date
August 14, 2015
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • Osteoporosis patients with normal walking speed is within between 0\.5m/sec and 1\.2m/sec.

Exclusion Criteria

  • Patients: those take psychotropic agents, or anabolic agents, etc., and those physical performances are diagnosed to be influenced by above agents. Patients received agents that affect bone metabolism within 8 weeks before the treatment start.
  • Patients with disease(s) accompanied by high risk of falls except for osteoporosis.
  • Patients with disease(s) characterized by low bone mass except for osteoporosis.

Outcomes

Primary Outcomes

Not specified

Similar Trials